population shows just the opposite (between 7 to 10 per 100,000 patients who received the BNT162b2 versus about 5 per 100,000 who received the mRNA1273 vaccine).īoth studies are consistent in reporting risk of myocarditis in adolescent and young adult males, and the fact that there is a higher incidence after the second dose. In the Nordic study published in JAMA Cardiology in April 2022 the incidence of myocarditis in young adolescent and adult males aged 16 to 24 was lower in those who received the BNT162b2 vaccine (4 to 7 per 100,000 vaccinated individuals) compared to the mRNA-1273 vaccine (9 to 28 per 100,000 vaccinated individuals) (1).
Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.